158 related articles for article (PubMed ID: 37036756)
21. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
[TBL] [Abstract][Full Text] [Related]
22. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
Reed DR; Mascarenhas L; Manning K; Hale GA; Goldberg J; Gill J; Sandler E; Isakoff MS; Smith T; Caracciolo J; Lush RM; Juan TH; Lee JK; Neuger AM; Sullivan DM
Cancer Med; 2016 Feb; 5(2):294-303. PubMed ID: 26714427
[TBL] [Abstract][Full Text] [Related]
23. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Davies JM; Dhruva NS; Walko CM; Socinski MA; Bernard S; Hayes DN; Kim WY; Ivanova A; Keller K; Hilbun LR; Chiu M; Dees EC; Stinchcombe TE
Lung Cancer; 2011 Feb; 71(2):151-5. PubMed ID: 20580118
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.
Ferrario C; Strepponi I; Esfahani K; Charamis H; Langleben A; Scarpi E; Nanni O; Miller WH; Panasci LC
PLoS One; 2016; 11(12):e0167906. PubMed ID: 27992451
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Hubbard JM; Kim G; Borad MJ; Johnson E; Qin R; Lensing J; Puttabasavaiah S; Wright J; Erlichman C; Grothey A
Invest New Drugs; 2016 Feb; 34(1):96-103. PubMed ID: 26581401
[TBL] [Abstract][Full Text] [Related]
28. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
[TBL] [Abstract][Full Text] [Related]
29. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Silk AW; Saraiya B; Groisberg R; Chan N; Spencer K; Girda E; Shih W; Palmeri M; Saunders T; Berman RM; Coric V; Chen S; Zloza A; Vieth J; Mehnert JM; Malhotra J
Eur J Med Res; 2022 Jul; 27(1):107. PubMed ID: 35780243
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Chan JA; Mayer RJ; Jackson N; Malinowski P; Regan E; Kulke MH
Cancer Chemother Pharmacol; 2013 May; 71(5):1241-6. PubMed ID: 23475104
[TBL] [Abstract][Full Text] [Related]
31. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Kim R; Prithviraj GK; Shridhar R; Hoffe SE; Jiang K; Zhao X; Chen DT; Almhanna K; Strosberg J; Campos T; Shibata D
Radiother Oncol; 2016 Feb; 118(2):382-6. PubMed ID: 26861740
[TBL] [Abstract][Full Text] [Related]
33. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Baselga J; Costa F; Gomez H; Hudis CA; Rapoport B; Roche H; Schwartzberg LS; Petrenciuc O; Shan M; Gradishar WJ
Trials; 2013 Jul; 14():228. PubMed ID: 23876062
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.
Mehnert JM; Silk AW; Lee JH; Dudek L; Jeong BS; Li J; Schenkel JM; Sadimin E; Kane M; Lin H; Shih WJ; Zloza A; Chen S; Goydos JS
Pigment Cell Melanoma Res; 2018 Jul; 31(4):534-540. PubMed ID: 29453787
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Nogova L; Mattonet C; Scheffler M; Taubert M; Gardizi M; Sos ML; Michels S; Fischer RN; Limburg M; Abdulla DSY; Persigehl T; Kobe C; Merkelbach-Bruse S; Franklin J; Backes H; Schnell R; Behringer D; Kaminsky B; Eichstaedt M; Stelzer C; Kinzig M; Sörgel F; Tian Y; Junge L; Suleiman AA; Frechen S; Rokitta D; Ouyang D; Fuhr U; Buettner R; Wolf J
Cancer Med; 2020 Jul; 9(14):4991-5007. PubMed ID: 32436621
[TBL] [Abstract][Full Text] [Related]
37. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
[TBL] [Abstract][Full Text] [Related]
38. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Ooka Y; Chiba T; Ogasawara S; Arai K; Suzuki E; Tawada A; Yamashita T; Kanai F; Kaneko S; Yokosuka O
Invest New Drugs; 2014 Aug; 32(4):723-8. PubMed ID: 24599799
[TBL] [Abstract][Full Text] [Related]
40. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
